PiggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts

Nucleic Acids Research

Volumn 44, Issue 2, 2016, Pages 744-760

  Loperfido, Mariana ^a,b   Jarmin, Susan ^c   Dastidar, Sumitava ^a   Di Matteo, Mario ^a,b   Perini, Ilaria ^d   Moore, Marc ^c   Nair, Nisha ^a   Samara Kuko, Ermira ^a   Athanasopoulos, Takis ^c,e   Tedesco, Francesco Saverio ^f   Dickson, George ^c   Sampaolesi, Maurilio ^d   VandenDriessche, Thierry ^a,b   Chuah, Marinee K ^a,b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; GREEN FLUORESCENT PROTEIN; TRANSPOSASE; DMD PROTEIN, HUMAN; TRANSPOSON;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; C2C12 MYOBLAST; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA SEQUENCE; DNA TRANSPOSITION; GENE DELIVERY SYSTEM; GENETIC CODE; GENETIC TRANSFECTION; GOLDEN RETRIEVER; HEMANGIOBLAST; MALE; MULTINUCLEAR CELL; MUSCLE STEM CELL; MUSCULAR DYSTROPHY; MYOBLAST; MYOTUBE; NONHUMAN; PERICYTE; PIGGYBAC TRANSPOSON; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE EXPRESSION; TRANSPOSASE GENE; TRANSPOSON; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CYTOLOGY; DOG; GENE THERAPY; GENETICS; HUMAN; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; PROCEDURES; SKELETAL MYOBLAST; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; DNA TRANSPOSABLE ELEMENTS; DOGS; DYSTROPHIN; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS, SKELETAL; STEM CELLS; TRANSFECTION;

EID: 84966373272     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkv1464     Document Type: Article

References (103)

1. Mendell,J.R. and Lloyd-Puryear,M. (2013) Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve, 48, 21-26.
2. Hoffman,E.P., Brown,R.H. and Kunkel,L.M. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 51, 919-928.
3. Bonilla,E., Samitt,C.E., Miranda,A.F., Hays,A.P., Salviati,G., DiMauro,S., Kunkel,L.M., Hoffman,E.P. and Rowland,L.P. (1988) Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell, 54, 447-452.
4. Ervasti,J.M. (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta, 1772, 108-117.
5. Mercuri,E. and Muntoni,F. (2013) Muscular dystrophies. Lancet, 381, 845-860.
6. Bushby,K., Finkel,R., Birnkrant,D.J., Case,L.E., Clemens,P.R., Cripe,L., Kaul,A., Kinnett,K., McDonald,C., Pandya,S. et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol., 9, 77-93.
7. Bushby,K., Finkel,R., Birnkrant,D.J., Case,L.E., Clemens,P.R., Cripe,L., Kaul,A., Kinnett,K., McDonald,C., Pandya,S. et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol., 9, 177-189.
8. Serra,F., Quarta,M., Canato,M., Toniolo,L., De Arcangelis,V., Trotta,A., Spath,L., Monaco,L., Reggiani,C. and Naro,F. (2012) Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve, 46, 773-784.
9. Mercuri,E. and Muntoni,F. (2015) Efficacy of idebenone in Duchenne muscular dystrophy. Lancet, 385, 1704-1706.
10. Benedetti,S., Hoshiya,H. and Tedesco,F.S. (2013) Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J., 280, 4263-4280.
11. Seto,J.T., Bengtsson,N.E. and Chamberlain,J.S. (2014) Therapy of genetic disorders-novel therapies for Duchenne muscular dystrophy. Curr. Pediatr. Rep., 2, 102-112.
12. Aartsma-Rus,A. (2010) Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol., 7, 453-461.
13. Mendell,J.R., Rodino-Klapac,L.R., Sahenk,Z., Roush,K., Bird,L., Lowes,L.P., Alfano,L., Gomez,A.M., Lewis,S., Kota,J. et al. (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol., 74, 637-647.
14. Emery,A.E.H. (2002) The muscular dystrophies. Lancet, 359, 687-695.
15. Helderman-van den Enden,A.T.J.M., Straathof,C.S.M., Aartsma-Rus,A., den Dunnen,J.T., Verbist,B.M., Bakker,E., Verschuuren,J.J.G.M. and Ginjaar,H.B. (2010) Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul. Disord., 20, 251-254.
16. van den Bergen,J.C., Schade van Westrum,S.M., Dekker,L., van der Kooi,A.J., de Visser,M., Wokke,B.H.A., Straathof,C.S., Hulsker,M.A., Aartsma-Rus,A., Verschuuren,J.J. et al. (2014) Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. J. Neurol. Neurosurg. Psychiatry, 85, 92-98.
17. Findlay,A.R., Wein,N., Kaminoh,Y., Taylor,L.E., Dunn,D.M., Mendell,J.R., King,W.M., Pestronk,A., Florence,J.M., Mathews,K.D. et al. (2015) Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45. Ann. Neurol., 77, 668-674.
18. Lu,Q.-L., Cirak,S. and Partridge,T. (2014) What can we learn from clinical trials of exon skipping for DMD? Mol. Ther. Nucleic Acids, 3, e152.
19. Koenig,M., Hoffman,E.P., Bertelson,C.J., Monaco,A.P., Feener,C. and Kunkel,L.M. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50, 509-517.
20. Muntoni,F., Torelli,S. and Ferlini,A. (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol., 2, 731-740.
21. Kawano,R., Ishizaki,M., Maeda,Y., Uchida,Y., Kimura,E. and Uchino,M. (2008) Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice. Mol. Ther., 16, 825-831.
22. Guse,K., Suzuki,M., Sule,G., Bertin,T.K., Tyynismaa,H., Ahola-Erkkilä,S., Palmer,D., Suomalainen,A., Ng,P., Cerullo,V. et al. (2012) Capsid-modified adenoviral vectors for improved muscle-directed gene therapy. Hum. Gene Ther., 23, 1065-1070.
23. Gregorevic,P., Blankinship,M.J., Allen,J.M., Crawford,R.W., Meuse,L., Miller,D.G., Russell,D.W. and Chamberlain,J.S. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med., 10, 828-834.
24. Gregorevic,P., Allen,J.M., Minami,E., Blankinship,M.J., Haraguchi,M., Meuse,L., Finn,E., Adams,M.E., Froehner,S.C., Murry,C.E. et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med., 12, 787-789.
25. Koppanati,B.M., Li,J., Xiao,X. and Clemens,P.R. (2009) Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Ther., 16, 1130-1137.
26. Rodino-Klapac,L.R., Montgomery,C.L., Bremer,W.G., Shontz,K.M., Malik,V., Davis,N., Sprinkle,S., Campbell,K.J., Sahenk,Z., Clark,K.R. et al. (2010) Persistent expression of FLAG-tagged micro dystrophin in nonhuman primates following intramuscular and vascular delivery. Mol. Ther., 18, 109-117.
27. Brunetti-Pierri,N., Palmer,D.J., Beaudet,A.L., Carey,K.D., Finegold,M. and Ng,P. (2004) Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther., 15, 35-46.
28. Wang,Z., Kuhr,C.S., Allen,J.M., Blankinship,M., Gregorevic,P., Chamberlain,J.S., Tapscott,S.J. and Storb,R. (2007) Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther., 15, 1160-1166.
29. Mingozzi,F., Meulenberg,J.J., Hui,D.J., Basner-Tschakarjan,E., Hasbrouck,N.C., Edmonson,S.A., Hutnick,N.A., Betts,M.R., Kastelein,J.J., Stroes,E.S. et al. (2009) AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood, 114, 2077-2086.
30. Wang,Z., Halbert,C.L., Lee,D., Butts,T., Tapscott,S.J., Storb,R. and Miller,A.D. (2014) Elimination of contaminating cap genes in AAV vector virions reduces immune responses and improves transgene expression in a canine gene therapy model. Gene Ther., 21, 363-370.
31. Wu,S.C.-Y., Meir,Y.-J.J., Coates,C.J., Handler,A.M., Pelczar,P., Moisyadi,S. and Kaminski,J.M. (2006) piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc. Natl. Acad. Sci. U.S.A., 103, 15008-15013.
32. Li,M.A., Turner,D.J., Ning,Z., Yusa,K., Liang,Q., Eckert,S., Rad,L., Fitzgerald,T.W., Craig,N.L. and Bradley,A. (2011) Mobilization of giant piggyBac transposons in the mouse genome. Nucleic Acids Res., 39, e148.
33. Ding,S., Wu,X., Li,G., Han,M., Zhuang,Y. and Xu,T. (2005) Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell, 122, 473-483.
34. Fraser,M.J., Brusca,J.S., Smith,G.E. and Summers,M.D. (1985) Transposon-mediated mutagenesis of a baculovirus. Virology, 145, 356-361.
35. Cary,L.C., Goebel,M., Corsaro,B.G., Wang,H.G., Rosen,E. and Fraser,M.J. (1989) Transposon mutagenesis of baculoviruses: analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. Virology, 172, 156-169.
36. Wilson,M.H., Coates,C.J. and George,A.L. (2007) PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther., 15, 139-145.
37. Yusa,K., Zhou,L., Li,M.A., Bradley,A. and Craig,N.L. (2011) A hyperactive piggyBac transposase for mammalian applications. Proc. Natl. Acad. Sci. U.S.A., 108, 1531-1536.
38. Doherty,J.E., Huye,L.E., Yusa,K., Zhou,L., Craig,N.L. and Wilson,M.H. (2012) Hyperactive piggyBac gene transfer in human cells and in vivo. Hum. Gene Ther., 23, 311-320.
39. Di Matteo,M., Belay,E., Chuah,M.K. and Vandendriessche,T. (2012) Recent developments in transposon-mediated gene therapy. Expert Opin. Biol. Ther., 12, 841-858.
40. Mitra,R., Fain-Thornton,J. and Craig,N.L. (2008) piggyBac can bypass DNA synthesis during cut and paste transposition. EMBO J., 27, 1097-1109.
41. Minasi,M.G., Riminucci,M., De Angelis,L., Borello,U., Berarducci,B., Innocenzi,A., Caprioli,A., Sirabella,D., Baiocchi,M., De Maria,R. et al. (2002) The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development, 129, 2773-2783.
42. Dellavalle,A., Sampaolesi,M., Tonlorenzi,R., Tagliafico,E., Sacchetti,B., Perani,L., Innocenzi,A., Galvez,B.G., Messina,G., Morosetti,R. et al. (2007) Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol., 9, 255-267.
43. Dellavalle,A., Maroli,G., Covarello,D., Azzoni,E., Innocenzi,A., Perani,L., Antonini,S., Sambasivan,R., Brunelli,S., Tajbakhsh,S. et al. (2011) Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat. Commun., 2, 499.
44. Sampaolesi,M., Torrente,Y., Innocenzi,A., Tonlorenzi,R., D'Antona,G., Pellegrino,M.A., Barresi,R., Bresolin,N., De Angelis,M.G.C., Campbell,K.P. et al. (2003) Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science, 301, 487-492.
45. Sampaolesi,M., Blot,S., D'Antona,G., Granger,N., Tonlorenzi,R., Innocenzi,A., Mognol,P., Thibaud,J.-L., Galvez,B.G., Barthélémy,I. et al. (2006) Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature, 444, 574-579.
46. Palumbo,R., Sampaolesi,M., De Marchis,F., Tonlorenzi,R., Colombetti,S., Mondino,A., Cossu,G. and Bianchi,M.E. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol., 164, 441-449.
47. Tedesco,F.S., Hoshiya,H., D'Antona,G., Gerli,M.F.M., Messina,G., Antonini,S., Tonlorenzi,R., Benedetti,S., Berghella,L., Torrente,Y. et al. (2011) Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci. Transl. Med., 3, 96ra78.
48. Domi,T., Porrello,E., Velardo,D., Capotondo,A., Biffi,A., Tonlorenzi,R., Amadio,S., Ambrosi,A., Miyagoe-Suzuki,Y., Takeda,S. et al. (2015) Mesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A. Skeletal Muscle, 5, 30.
49. Cossu,G., Previtali,S.C., Napolitano,S., Cicalese,M.P., Tedesco,F.S., Nicastro,F., Noviello,M., Roostalu,U., Natali Sora,M.G., Scarlato,M. et al. (2015) Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol. Med., e201505636.
50. Schrepfer,S., Deuse,T., Reichenspurner,H., Fischbein,M.P., Robbins,R.C. and Pelletier,M.P. (2007) Stem cell transplantation: the lung barrier. Transplant. Proc., 39, 573-576.
51. Sharma,R.R., Pollock,K., Hubel,A. and McKenna,D. (2014) Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion, 54, 1418-1437.
52. Yaffe,D. and Saxel,O. (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature, 270, 725-727.
53. Tonlorenzi,R., Dellavalle,A., Schnapp,E., Cossu,G. and Sampaolesi,M. (2007) Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr. Protoc. Stem Cell Biol., doi:10.1002/9780470151808.sc02b01s3.
54. Di Matteo,M., Samara-Kuko,E., Ward,N.J., Waddingon,S.N., McVey,J.H., Chuah,M.K.L. and VandenDriessche,T. (2014) Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Mol. Ther., 22, 1614-1624.
55. Li,X., Lobo,N., Bauser,C.A. and Fraser,M.J. (2001) The minimum internal and external sequence requirements for transposition of the eukaryotic transformation vector piggyBac. Mol. Genet. Genomics, 266, 190-198.
56. Li,X., Harrell,R.A., Handler,A.M., Beam,T., Hennessy,K. and Fraser,M.J. (2005) piggyBac internal sequences are necessary for efficient transformation of target genomes. Insect Mol. Biol., 14, 17-30.
57. Li,X., Eastman,E.M., Schwartz,R.J. and Draghia-Akli,R. (1999) Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol., 17, 241-245.
58. Koo,T., Malerba,A., Athanasopoulos,T., Trollet,C., Boldrin,L., Ferry,A., Popplewell,L., Foster,H., Foster,K. and Dickson,G. (2011) Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice. Hum. Gene Ther., 22, 1379-1388.
59. Athanasopoulos,T., Foster,H., Foster,K. and Dickson,G. (2011) Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy. Methods Mol. Biol., 709, 21-37.
60. VandenDriessche,T., Ivics,Z., Izsvák,Z. and Chuah,M.K.L. (2009) Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood, 114, 1461-1468.
61. Kimura,E., Han,J.J., Li,S., Fall,B., Ra,J., Haraguchi,M., Tapscott,S.J. and Chamberlain,J.S. (2008) Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum. Mol. Genet., 17, 2507-2517.
62. Ross,J.J., Hong,Z., Willenbring,B., Zeng,L., Isenberg,B., Lee,E.H., Reyes,M., Keirstead,S.A.,Weir,E.K., Tranquillo,R.T. et al. (2006) Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells. J. Clin. Invest., 116, 3139-3149.
63. Livak,K.J. and Schmittgen,T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
64. Rincon,M.Y., Sarcar,S., Danso-Abeam,D., Keyaerts,M., Matrai,J., Samara-Kuko,E., Acosta-Sanchez,A., Athanasopoulos,T., Dickson,G., Lahoutte,T. et al. (2014) Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional cis-regulatory motifs that enable efficient cardiac gene therapy. Mol. Ther., 23, 43-52.
65. Burnight,E.R., Staber,J.M., Korsakov,P., Li,X., Brett,B.T., Scheetz,T.E., Craig,N.L. and McCray,P.B. (2012) A hyperactive transposase promotes persistent gene transfer of a piggyBac DNA transposon. Mol. Ther. Nucleic Acids, 1, e50.
66. Sharma,N., Cai,Y., Bak,R.O., Jakobsen,M.R., Schrøder,L.D. and Mikkelsen,J.G. (2013) Efficient sleeping beauty DNA transposition from DNA minicircles. Mol. Ther. Nucleic Acids, 2, e74.
67. Muses,S., Morgan,J.E. and Wells,D.J. (2011) A new extensively characterised conditionally immortal muscle cell-line for investigating therapeutic strategies in muscular dystrophies. PloS One, 6, e24826.
68. Quattrocelli,M., Palazzolo,G., Floris,G., Schöffski,P., Anastasia,L., Orlacchio,A., Vandendriessche,T., Chuah,M.K.L., Cossu,G., Verfaillie,C. et al. (2011) Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J. Pathol., 223, 593-603.
69. Ley,D., Van Zwieten,R., Puttini,S., Iyer,P., Cochard,A. and Mermod,N. (2014) A PiggyBac-mediated approach for muscle gene transfer or cell therapy. Stem Cell Res., 13, 390-403.
70. Muses,S., Morgan,J.E. and Wells,D.J. (2011) Restoration of dystrophin expression using the Sleeping Beauty transposon. PLoS Curr., 3, RRN1296.
71. Filareto,A., Parker,S., Darabi,R., Borges,L., Iacovino,M., Schaaf,T., Mayerhofer,T., Chamberlain,J.S., Ervasti,J.M., McIvor,R.S. et al. (2013) An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat. Commun., 4, 1549.
72. Nakazawa,Y., Huye,L.E., Dotti,G., Foster,A.E., Vera,J.F., Manuri,P.R., June,C.H., Rooney,C.M. and Wilson,M.H. (2009) Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J. Immunother., 32, 826-836.
73. Belay,E., Dastidar,S., VandenDriessche,T. and Chuah,M.K.L. (2011) Transposon-mediated gene transfer into adult and induced pluripotent stem cells. Curr. Gene Ther., 11, 406-413.
74. Kouprina,N., Tomilin,A.N., Masumoto,H., Earnshaw,W.C. and Larionov,V. (2014) Human artificial chromosome-based gene delivery vectors for biomedicine and biotechnology. Expert Opin. Drug Deliv., 11, 517-535.
75. Tedesco,F.S. (2015) Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes. Chromosome Res., 23, 135-141.
76. Hoshiya,H., Kazuki,Y., Abe,S., Takiguchi,M., Kajitani,N., Watanabe,Y., Yoshino,T., Shirayoshi,Y., Higaki,K., Messina,G. et al. (2009) A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene. Mol. Ther., 17, 309-317.
77. Kazuki,Y., Hiratsuka,M., Takiguchi,M., Osaki,M., Kajitani,N., Hoshiya,H., Hiramatsu,K., Yoshino,T., Kazuki,K., Ishihara,C. et al. (2010) Complete genetic correction of ips cells from Duchenne muscular dystrophy. Mol. Ther., 18, 386-393.
78. Tedesco,F.S., Gerli,M.F.M., Perani,L., Benedetti,S., Ungaro,F., Cassano,M., Antonini,S., Tagliafico,E., Artusi,V., Longa,E. et al. (2012) Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci. Transl. Med., 4, 140ra89.
79. Arechavala-Gomeza,V., Anthony,K., Morgan,J. and Muntoni,F. (2012) Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges. Curr. Gene Ther., 12, 152-160.
80. Echigoya,Y. and Yokota,T. (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther., 24, 57-68.
81. Li,H.L., Fujimoto,N., Sasakawa,N., Shirai,S., Ohkame,T., Sakuma,T., Tanaka,M., Amano,N., Watanabe,A., Sakurai,H. et al. (2015) Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep., 4, 143-154.
82. Ousterout,D.G., Kabadi,A.M., Thakore,P.I., Perez-Pinera,P., Brown,M.T., Majoros,W.H., Reddy,T.E. and Gersbach,C.A. (2015) Correction of dystrophin expression in cells from duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases. Mol. Ther., 23, 523-532.
83. Ousterout,D.G., Kabadi,A.M., Thakore,P.I., Majoros,W.H., Reddy,T.E. and Gersbach,C.A. (2015) Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun., 6, 6244.
84. Mátés,L., Chuah,M.K.L., Belay,E., Jerchow,B., Manoj,N., Acosta-Sanchez,A., Grzela,D.P., Schmitt,A., Becker,K., Matrai,J. et al. (2009) Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet., 41, 753-761.
85. Belay,E., Mátrai,J., Acosta-Sanchez,A., Ma,L., Quattrocelli,M., Mátés,L., Sancho-Bru,P., Geraerts,M., Yan,B., Vermeesch,J. et al. (2010) Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. Stem Cells, 28, 1760-1771.
86. Grabundzija,I., Irgang,M., Mátés,L., Belay,E., Matrai,J., Gogol-Döring,A., Kawakami,K., Chen,W., Ruiz,P., Chuah,M.K.L. et al. (2010) Comparative analysis of transposable element vector systems in human cells. Mol. Ther., 18, 1200-1209.
87. Krieg,A.M., Yi,A.K., Matson,S., Waldschmidt,T.J., Bishop,G.A., Teasdale,R., Koretzky,G.A. and Klinman,D.M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374, 546-549.
88. Reyes-Sandoval,A. and Ertl,H.C.J. (2004) CpG methylation of a plasmid vector results in extended transgene product expression by circumventing induction of immune responses. Mol. Ther., 9, 249-261.
89. Yew,N.S., Przybylska,M., Ziegler,R.J., Liu,D. and Cheng,S.H. (2001) High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol. Ther., 4, 75-82.
90. Hyde,S.C., Pringle,I.A., Abdullah,S., Lawton,A.E., Davies,L.A., Varathalingam,A., Nunez-Alonso,G., Green,A.-M., Bazzani,R.P., Sumner-Jones,S.G. et al. (2008) CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat. Biotechnol., 26, 549-551.
91. Lukacs,G.L., Haggie,P., Seksek,O., Lechardeur,D., Freedman,N. and Verkman,A.S. (2000) Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem., 275, 1625-1629.
92. Cadiñanos,J. and Bradley,A. (2007) Generation of an inducible and optimized piggyBac transposon system. Nucleic Acids Res., 35,e87.
93. Biasco,L., Baricordi,C. and Aiuti,A. (2012) Retroviral integrations in gene therapy trials. Mol. Ther., 20, 709-716.
94. Wilson,M.H. and George,A.L. (2010) Designing and testing chimeric zinc finger transposases. Methods Mol. Biol., 649, 353-363.
95. Kettlun,C., Galvan,D.L., George,A.L., Kaja,A. and Wilson,M.H. (2011) Manipulating piggyBac transposon chromosomal integration site selection in human cells. Mol. Ther., 19, 1636-1644.
96. Wells,D.J., Wells,K.E., Asante,E.A., Turner,G., Sunada,Y., Campbell,K.P., Walsh,F.S. and Dickson,G. (1995) Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum. Mol. Genet., 4, 1245-1250.
97. Neri,M., Torelli,S., Brown,S., Ugo,I., Sabatelli,P., Merlini,L., Spitali,P., Rimessi,P., Gualandi,F., Sewry,C. et al. (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord., 17, 913-918.
98. Holliday,R. (2014) The commitment of human cells to senescence. Interdiscip. Top. Gerontol., 39, 1-7.
99. Marg,A., Escobar,H., Gloy,S., Kufeld,M., Zacher,J., Spuler,A., Birchmeier,C., Izsvák,Z. and Spuler,S. (2014) Human satellite cells have regenerative capacity and are genetically manipulable. J. Clin. Invest., 124, 4257-4265.
100. Costamagna,D., Berardi,E., Ceccarelli,G. and Sampaolesi,M. (2015) Adult stem cells and skeletal muscle regeneration. Curr. Gene Ther. 15 , 348-363.
101. Gerli,M.F.M., Maffioletti,S.M., Millet,Q. and Tedesco,F.S. (2014) Transplantation of induced pluripotent stem cell-derived mesoangioblast-like myogenic progenitors in mouse models of muscle regeneration. J. Vis. Exp., 83, e50532.
102. Maffioletti,S.M., Gerli,M.F.M., Ragazzi,M., Dastidar,S., Benedetti,S., Loperfido,M., VandenDriessche,T., Chuah,M.K. and Tedesco,F.S. (2015) Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat. Protoc., 10, 941-958.
103. Loperfido,M., Steele-Stallard,H.B., Tedesco,F.S. and VandenDriessche,T. (2015) Pluripotent Stem Cells for Gene Therapy of Degenerative Muscle Diseases. Curr. Gene Ther. 15, 364-380.